Archives

Proprietary immuno-oncology approach harnesses
autologous dendritic cell therapy to treat an orphan-designated cancer

`s-Hertogenbosch,
The Netherlands, 18 March 2019.
Amphera B.V., an advanced-clinical-stage biotechnology company developing
dendritic cell therapies to treat cancer, announces that it has recruited the
first patients to its pivotal phase II/III study of MesoPher to treat pleural
mesothelioma, a rare cancer of the lining of the lungs.

DENIM (DENdritic cell Immunotherapy for Mesothelioma) is
an open-label, randomised, phase II/III study in 230 adults with pleural
mesothelioma, to assess the efficacy and anti-tumour activity of MesoPher as
maintenance treatment after chemotherapy. Patients in Arm A will receive 3
bi-weekly injections of MesoPher with best supportive care, plus